MEDP

MEDPACE HOLDINGS INC

Healthcare | Large Cap

$4.10

EPS Forecast

$708.3

Revenue Forecast

The company already released most recent quarter's earnings. We will publish our AI's next quarter's forecast around 2026-07-20

Medpace Q1 2026: Revenue Rises on Backlog, But Margins and Backlog Signals Prompt a Cautious Read for MEDP

Medpace Holdings, Inc. (MEDP) reported first-quarter 2026 results that confirm a robust top-line trajectory and a solid cash position, with GAAP earnings per diluted share (EPS) of 4.28 and a revenue forecast for the full year 2026 of $2.755 billion to $2.855 billion. The company’s EPS figure and revenue forecast sit alongside a net book-to-bill ratio of 0.88x and a backlog of $2,929.2 million, inviting a nuanced interpretation of the pace of demand and margin discipline. While the press release highlights meaningful year-over-year revenue growth, it also flags margin dynamics and a relatively modest backlog conversion, which will be of interest to investors watching earnings surprise dynamics and the EPS consensus for the rest of 2026.

Overview of the Quarter

Medpace reported revenue of $706.6 million for the three months ended March 31, 2026, up 26.5% from $558.6 million in the prior-year period. On a constant currency basis, the growth rate was 25.8%, underscoring that the lift is not merely a translation effect. The press release frames the quarter as a solid start to 2026, with several moving parts to watch across the year.

Key Metrics that Tell the Tale

  • Net new business awards were $618.4 million in Q1 2026, contributing to a backlog of $2,929.2 million as of March 31, 2026 (up 2.9% versus March 31, 2025).
  • The net book-to-bill ratio stood at 0.88x for the quarter, a useful signal of the balance between new orders and revenue in-flight.
  • GAAP net income for Q1 2026 was $123.9 million, or $4.28 per diluted share, vs. $114.6 million, or $3.67 per diluted share, in the prior-year period. Net income margin was 17.5% for Q1 2026, compared with 20.5% in Q1 2025.
  • EBITDA rose to $149.4 million in Q1 2026, representing an EBITDA margin of 21.1%—a healthy figure, though the margin pace softened versus the prior year (21.2%).
  • Operating cash flow was strong, with cash and cash equivalents of $652.7 million at March 31, 2026, and cash flow from operating activities of $151.8 million in the quarter.
  • Total direct costs were $510.3 million and SG&A expenses were $47.9 million for the quarter, signaling a relatively efficient cost base even as revenue scales.

Guidance and Implications for 2026

Looking ahead, Medpace provided a revenue forecast for the full year 2026 in the range of $2.755 billion to $2.855 billion, implying growth of roughly 8.9% to 12.8% versus 2025 revenue of $2.530 billion. The company also projects GAAP net income for the full year 2026 in the range of $487.0 million to $511.0 million, and EBITDA guidance of $605.0 million to $635.0 million. Diluted EPS is forecast to span $16.68 to $17.50, with an assumed tax rate of 19.0% to 20.0% and interest income of about $27.5 million.

The framing here matters for EPS consensus expectations across the analyst community, because while the company presents a coherent growth and profitability story, the magnitude of the improvement in margins and the resilience of backlog will influence the degree to which the market assigns a premium or a cautious multiple to MEDP for 2026. In short, the revenue forecast looks constructive, but the margin dynamics—evidenced by the Q1 margin and 2026 guidance—will be the focal point for evaluating how much of the growth translates into sustainable earnings power.

Balance Sheet and Liquidity: A Comfortable Position

The company’s liquidity profile remains solid. Cash and cash equivalents of $652.7 million at March 31, 2026, and a strong operating cash flow base support ongoing investments in clinical capabilities and potential business development. The balance sheet backdrop matters because, in a capital-intensive sector like outsourced clinical research services, liquidity cushions help mitigate cycle risk amid competitive intensity and inquiries into contract pricing discipline.

Implications for Medpace and Sector Peers

The first-quarter print reinforces a familiar macro theme for contract research organizations: outsized demand for outsourcing keeps revenue moving, but the real question is whether the backlog accelerates in a meaningful way or remains a lever for volume while margin discipline remains a work in progress. A net book-to-bill near 1.0x or below often signals that tooms exist for continued growth, but it also invites scrutiny of pricing power and operational leverage.

For MEDP and peers, the key takeaways are twofold. First, the growth cadence—supported by a 25%+ revenue lift in constant currency—suggests durable top-line momentum. Second, the margin trajectory, with GAAP net income margins compressing versus the prior year and EBITDA margin hovering around the low 21% range, indicates investments to sustain growth may weigh on near-term profitability. Investors will watch how sustained the revenue mix translates into earnings power, especially as the company navigates a favorable but not limitless cash-flow runway.

In the broader CRO space, these dynamics often translate into a competition for more favorable terms with sponsors, a push to expand higher-margin services (e.g., specialized analytics, faster-study designs), and a continued emphasis on diversified late-stage and early-phase programs. If MEDP can maintain or expand operating leverage against a backdrop of steady demand, the comparison set—other public CROs with similar scale—may benefit from a constructive reassessment of their own revenue forecast resilience and EPS consensus trajectories for 2026 and beyond.

Bottom Line

Medpace’s Q1 2026 results present a solid foundation: revenue growth well into the mid–double digits, a constructive revenue forecast for the year, meaningful EPS progression, and a healthy cash position. The caveat is that margins and backlog dynamics could temper the pace of upside unless the company sustains demand momentum and improves unit profitability. For MEDP and its sector peers, the quarter reads as a reminder that growth remains supported by external demand, but investors will reward clarity on how much of that growth translates into durable earnings and free cash flow in 2026.

Note: This summary references the quarter ended March 31, 2026, and the guidance published for full-year 2026. All figures are GAAP unless noted otherwise in the source document.